Get the app
Salim Syed
Senior biotech analyst at Mizuho providing market analysis and company-specific insights on therapeutics, launches, and clinical catalysts across biotech companies.
Best podcasts with Salim Syed
Ranked by the Snipd community
Jan 7, 2026
• 32min
Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year
chevron_right
Salim Syed, a senior biotech analyst at Mizuho, dives into the latest trends in the biotech sector. He shares insights on BridgeBio's expected revenues and the launch of Truvy, forecasting significant market potential. The conversation shifts to Cytokinetics' Mycorzo approval and its advantages over competitors. Syed discusses Vaxcyte's promising guidance and upcoming trial data, while also highlighting Biogen's catalysts and Arcus' strong product potential. His expertise sheds light on critical developments as the new year approaches.
The AI-powered Podcast Player
Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
Get the app
